Raia Drogasil stock
Price history
−39.68% over the period1 year: from R$22.75 (November 24, 2025) to R$13.72 (November 22, 2026), −39.68%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 22, 2026 | R$13.72 |
| October 30, 2026 | R$15.22 |
| September 30, 2026 | R$18.37 |
| August 31, 2026 | R$19.60 |
| July 31, 2026 | R$18.48 |
| June 30, 2026 | R$16.81 |
| May 29, 2026 | R$18.69 |
| April 30, 2026 | R$21.94 |
| March 31, 2026 | R$23.53 |
| February 27, 2026 | R$25.08 |
| January 30, 2026 | R$24.50 |
| December 30, 2025 | R$23.45 |
| November 28, 2025 | R$23.54 |
| November 24, 2025 | R$22.75 |
At a glance
The company
Retail seller of medicines, perfumery, personal care, beauty products and cosmetics in Brazil
Latest results
Quarter to September 30, 2026 · EPS R$0.24 (estimate R$0.25)
TickerLandia's take on Raia Drogasil
- Cheaper than usual relative to earnings: P/E on the latest fiscal year 18 vs a median of 46 over its last 10 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 18 vs 14 (+22%) in a group of 10.
- Strong point: Earnings stability (73/100 in its group). Weak point: Market momentum (12/100).
- “Below historical valuation” (Brazil): No. 4 of 33.
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−49.96% from the 52-week high
Analysts · 15 analysts
Average targetR$23.37+70.31% vs. price
Buy 13 · Hold 1 · Sell 1 · Buy
TickerLandia Fingerprint: Raia Drogasil
Compared with similar companies: very weak momentum.
Financials and price compared with 130 companies in related industries (retail), worldwide. Momentum and risk compared with 317 Latin American stocks.
Pricelow34
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 17.6 42 Forward P/E 12.5 29 EV/EBITDA 8.45 20 Price/book 3.18 52 Price/sales 0.51 28 Profitabilityaverage48
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 30.9% 40 Operating margin 6.1% 43 Net margin 2.7% 29 ROE 19.7% 57 ROA 7.3% 69 Earnings stabilityhigh73
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 0.4% 86 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 61 Growthaverage55
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +7.80% 59 Earnings growth (year over year) −8.80% 26 Average revenue growth (3 years) +15.04% 81 Financial strengthaverage41
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage 2.49 19 Net debt/EBITDAcounts in reverse: lower means more financial strength 2.36 42 Debt/equitycounts in reverse: lower means more financial strength 1.17 39 Current ratio 1.40 63 Dividendhigh64
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years 20 years 57 Payout ratio 57.8% 67 Dividend yield 3.3% 69 Market momentumvery weak12
How the stock has moved compared with the market.
Metric Value Position in group Distance from 200-day average −31.62% 10 1-year return −39.68% 11 Relative strength (3 months) −21.90% 7 Relative strength (6 months) −22.44% 20 Riskhigh78
How much the price swings.
Metric Value Position in group Volatility (60 days) 65.2% 82 Beta (1 year) 1.41 66 Maximum drawdown (12 months) 49.2% 85
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Raia Drogasil is cheaper than in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), Raia Drogasil's P/E today is 17.5, below the median of its last 10 fiscal years (46.2; between 30.0 and 85.5 from 2016 to 2025). Raia Drogasil's P/E (trailing 12 months): 17.6, +22% against the median of a group of 10 similar companies (14.4).
Compared with 10 similar companies
| Metric | Raia Drogasil | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 17.6 | High | |
| Forward P/E | 12.5 | Middle | |
| Operating margin | 6.1% | Middle | |
| ROE | 19.7% | High | |
| Debt/equity | 1.17 | High |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Raia Drogasil. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
R$11.41B
Latest quarter · Q3 2026
Net income
R$408.25M
Latest quarter · Q3 2026
Quarterly net margin
3.6%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- R$23.99B
- P/E
- 17.6
- EPS
- R$0.78
- Volume
- 9.38M
- Daily trading
- €35.3M
- Dividend yield
- 3.28%
- Last ex-dividend on October 8, 2026
How Raia Drogasil is changing
All resultsRevenue grew 17.1% a year on average over the last 5 years
Free cash flow equal to 84% of net income
Shares outstanding down 5.4% in 5 years
Returns
Raia Drogasil returns with dividends
R$1,000 invested in Raia Drogasil 5 years ago, on November 22, 2021, would be worth R$673 today with dividends reinvested: −32.72% in total, −7.62% per year. On price alone it would be R$624 (−37.64%).
| Period | Raia Drogasil | Ibovespa | R$1,000 becomes |
|---|---|---|---|
| 1 month | −32.48% | −18.87% | R$675 |
| 6 months | −24.57% | −5.58% | R$754 |
| Year to date | −41.49% | +3.26% | R$585 |
| 1 year | −38.36% | +7.15% | R$616 |
| 3 years | −47.96% | +32.01% | R$520 |
| 5 years | −32.72% | +62.92% | R$673 |
| 10 years | +23.96% | +168.55% | R$1,240 |
Over the last 6 months it has done better than 12% of the stocks in the Consumer sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. Ibovespa: with dividends. Calculate your investment
The chart in detail
Raia Drogasil: technical analysis
Raia Drogasil is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 53.5% below its all-time closing high (R$29.48, August 5, 2024).
- Trend
- Downward
- RSI (14 sessions)
- 25
- Below 30: a strong fall in a short time
- vs 200-session average
- −31.40%
Active signals
RSI below 30: the stock has fallen a lot in a short time.
since November 5, 2026
Support and resistance
Price areas where Raia Drogasil has stopped several times in the last year. They describe the chart; they are not forecasts.
- ResistanceR$17.62+28.41%4 touches, last on September 28, 2026
- ResistanceR$17.08+24.49%2 touches, last on August 18, 2026
- ResistanceR$16.28+18.62%2 touches, last on June 30, 2026
- Last priceR$13.72
- No support below: the price is near the lows of the year
Volatility and risk
Over the last year it has moved more than the Ibovespa.
- Beta (1 year) vs Ibovespa
- 1.41
- Volatility (60 sessions, annualised)
- 65.2%
- Largest fall in the last year
- −49.19%
In session, November 22, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Raia Drogasil: seasonality
Average monthly price change over 27 years
Over the last 27 years, the strongest month for Raia Drogasil has been June: +18.01% on average, positive in 13 years out of 27. The weakest has been January: −0.13% on average, positive in 9 years out of 26. November, the current month, has been positive in 11 years out of 26 (+13.68% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | −0.13% | 0.00% | 9 of 26 |
| February | +4.79% | +0.86% | 14 of 27 |
| March | +2.81% | +1.91% | 17 of 27 |
| April | +2.03% | +0.74% | 14 of 27 |
| May | +1.74% | 0.00% | 11 of 27 |
| June | +18.01% | 0.00% | 13 of 27 |
| July | +3.62% | +4.00% | 16 of 27 |
| August | +0.54% | 0.00% | 12 of 27 |
| September | +1.58% | 0.00% | 13 of 27 |
| October | +1.03% | 0.00% | 11 of 27 |
| November | +13.68% | 0.00% | 11 of 26 |
| December | +1.86% | 0.00% | 11 of 26 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Raia Drogasil and its competitors
Raia Drogasil's sales are made in Brazil, where the company runs a retail network selling pharmaceutical and health goods. Its range covers medicines of several kinds, perfumery, personal care and beauty lines, cosmetics, dermocosmetics and specialty drugs. Customers buy through physical stores, while telesales and call centers serve as additional routes to market. The company's activity is concentrated on the domestic market, and the group traces its origins back to 1905.
- Headquarters
- São Paulo, Brazil
- Employees
- 77,428
- Founded
- 1905
- Chief executive
- Renato Raduan
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Raia DrogasilRADL3 | $4.04B | 6.1% | 17.6 | −24.57% |
| Alibaba Health Information Tech0241 | $5.4B | 5.3% | 20.1 | −33.12% |
| Redcare PharmacyRDC | $1.47B | 0.3% | — | +36.52% |
| JD Health International6618 | $13.26B | 6.1% | 15.0 | −19.27% |
| InRetail PerúINRETC1 | $3.97B | 9.2% | 13.5 | +22.03% |
| CencosudCENCOSUD | $4.56B | 4.9% | 23.8 | −22.16% |
Same industry or related industries, similar size. Compare Raia Drogasil with its competitors · Full profile
